New Oral Antithrombotic Drugs

Authors

  • Vana Christopoulou Cokkinou

DOI:

https://doi.org/10.2015/hc.v1i2.10

Keywords:

Oral antithrombotics, triclopidine, clopidogrel, ximelagatran, thromboembolic disease

Abstract

New oral antithrombotic drugs are currently used for several indications, but mostly for the long-term treatment or prevention of thromboembolic disease in situations such as high-risk orthopedic surgery, deep vein thrombosis and myocardial infarction. They are also used in atrial fibrillation for the prevention of stroke. This family of drugs includes anti-platelet agents, eg. ticlopidine and clopidogrel, antithrombin agents, eg. ximelagatran and several others with various mechanisms of action. Oral intake has to fulfill certain conditions regarding absorption, efficacy and safety.

Downloads

Issue

Vol. 1 No. 2 (2006)

Section

REVIEWS

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).